N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.27 NOK -2.24% Market Closed
Market Cap: 741.3m NOK

Nykode Therapeutics ASA
Change in Working Capital

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Nykode Therapeutics ASA
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
N
Nykode Therapeutics ASA
OSE:NYKD
Change in Working Capital
-$11.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Change in Working Capital
-kr102.9m
CAGR 3-Years
N/A
CAGR 5-Years
-75%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Change in Working Capital
-kr1.9m
CAGR 3-Years
23%
CAGR 5-Years
22%
CAGR 10-Years
-6%
C
Circio Holding ASA
OSE:CRNA
Change in Working Capital
-kr6.9m
CAGR 3-Years
N/A
CAGR 5-Years
13%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Change in Working Capital
kr2.6m
CAGR 3-Years
-55%
CAGR 5-Years
-38%
CAGR 10-Years
-18%
Zelluna ASA
OSE:ZLNA
Change in Working Capital
-kr12.9m
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nykode Therapeutics ASA
Glance View

Market Cap
742.3m NOK
Industry
Biotechnology

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

NYKD Intrinsic Value
0.49 NOK
Overvaluation 78%
Intrinsic Value
Price
N

See Also

What is Nykode Therapeutics ASA's Change in Working Capital?
Change in Working Capital
-11.2m USD

Based on the financial report for Sep 30, 2025, Nykode Therapeutics ASA's Change in Working Capital amounts to -11.2m USD.

What is Nykode Therapeutics ASA's Change in Working Capital growth rate?
Change in Working Capital CAGR 1Y
65%

Over the last year, the Change in Working Capital growth was 65%.

Back to Top